Axsome Therapeutics, Inc. (NASDAQ ... This article provides a comprehensive analysis of Axsome's current position, future prospects, and potential challenges in the competitive CNS drug market.

UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued ...

Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ ... or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Beyond AXS-05 and AUVELITY, Axsome has a robust pipeline that could drive future growth ... In conclusion, Axsome Therapeutics presents a compelling investment case with its strong commercial ...

Beyond AXS-05 and AUVELITY, Axsome has a robust pipeline that could drive future growth. AXS-07 for acute migraine ... In conclusion, Axsome Therapeutics presents a compelling investment case with its ...